Scholarlink

<p>When people suffering from cancer additionally have a rheumatic inflammatory disease, there is always the worry that due to the treatment, which in the broadest sense works on the immune system, could increase the probability of a recurrence of the tumor or a second malignancy. The choice of the most suitable disease-modifying antirheumatic drug then becomes difficult. Most recently, for this complex question the meaningful recommendations or so-called points to consider (PTC) of the European Alliance of Associations for Rheumatology (EULAR) can be referred to.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rheumatologische Basistherapie und maligne Erkrankungen

  • 期刊论文

  • 发表日期：

    2025年7月30日

查看全文
  • Marc Schmalzing

摘要

When people suffering from cancer additionally have a rheumatic inflammatory disease, there is always the worry that due to the treatment, which in the broadest sense works on the immune system, could increase the probability of a recurrence of the tumor or a second malignancy. The choice of the most suitable disease-modifying antirheumatic drug then becomes difficult. Most recently, for this complex question the meaningful recommendations or so-called points to consider (PTC) of the European Alliance of Associations for Rheumatology (EULAR) can be referred to.